Company Focus
Eli Lilly & Company
Latest Eli Lilly & Company News
Pharmaceutical
The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) revolutionizing the way the condition is treated. 11 April 2025
Related News
Insights
Company Spotlight
A late-stage clinical biotechnology company pioneering physics-based therapeutic approaches to treatments.
Latest News & Features of interest to Eli Lilly & Company
Pharmaceutical
USA and UK-based KalVista Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Ekterly (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. 7 July 2025
Biotechnology
Austria’s HeartBeat.bio and biotx.ai have announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. 7 July 2025
Biosimilars
Indian biosimilars company Biocon Biologics, a subsidiary of Biocon, today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorizations for Vevzuo and Evfraxy, biosimilars of Amgen’s (Nasdaq: AMGN) denosumab (trade names Xgeva and Prolia). 7 July 2025
Pharmaceutical
A Dutch appeals court has ruled that health insurers acted unlawfully in their group tender for three CDK 4/6 inhibitors, reigniting debate over cost-driven drug policies in the Netherlands. The case centered on whether insurers can restrict prescribing choices for innovative cancer drugs that differ in clinical profiles. 7 July 2025
Biotechnology
US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate CPTX2309, for up to $2.1 billion. Organon posted disappointing mid-stage trial results for its investigational endometriosis pain drug, OG-6219. Also of note last week, the US Food and drug Administration (FDA) granted accelerated approval for Regeneron’s multiple myeloma drug Lynozyfic. 6 July 2025
Pharmaceutical
Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a privately-held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. 4 July 2025
Pharmaceutical
US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. 4 July 2025
Biosimilars
Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for Vevzuo and Evfraxy biosimilars of denosumab, originated by Amgen. 4 July 2025
Pharmaceutical
A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis. 4 July 2025
Biotechnology
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter. 4 July 2025
Latest In Brief for Eli Lilly & Company
Pharmaceutical
Japan’s Nxera Pharma is to receive a $4.8 million milestone payment from UK pharma company Centessa Pharmaceuticals as part of the firms’ research collaboration. 7 July 2025
Latest Related Ones To Watch News
US CAR-T focused biotech CARGO Therapeutics today announced that it has entered into a definitive merger agreement with Concentra Biosciences, initially worth roughly $200 million. The news sent CARGO’s stock up as much as 9.6% to $4.81 in pre-market activity. 8 July 2025
30 June 2025
17 June 2025
16 June 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze